source
- FDA accepts new submission for Biohaven’s Vyglxia, opening path to approvalBiohaven announced that the FDA has accepted a refreshed application for its rare disease drug Vyglxia, which targets a nerve‑damaging disorder. Vyglxia is being developed for spinocerebellar atax…
- Compounding pharmacy recalls copycat version of Eli Lilly’s Zepbound amid safety concernsApothecary Pharma, a compounding pharmacy, has voluntarily recalled its compounded tirzepatide product that mimics Eli Lilly's obesity drug Zepbound. The company said it could not guarantee the saf…